[Dissolution of gallstones by chenodeoxycholic acid].
A 2-year prospective study with chenodeoxycholic acid (CDCA) (750 mg per day) was performed in 34 asymptomatic patients with radiolucent gallstones. 17 patients dropped out before completion of the trial. In 5 cases (29%) the stones dissolved and in 5 additional cases they decreased in size, while in 2 cases (13%) they increased in size during treatment. Favorable criteria for dissolution were round stones without edges and fissures on radiological appearance and a stone diameter of less than 1 cm. In 3 cases drug-induced nausea or diarrhea were so pronounced that treatment could not be continued. CDCA treatment also caused a significant rise in SGPT for at least one year. Thus, CDCA is at best moderately effective in a highly selective group of patients with gallstones.
D001219:Aspartate Aminotransferases / Q000097:blood; D002635:Chenodeoxycholic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D002769:Cholelithiasis / Q000097:blood / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D014280:Triglycerides / Q000097:blood
D014280:Triglycerides; D002635:Chenodeoxycholic Acid; D001219:Aspartate Aminotransferases
Auflösung von Gallensteinen durch Chenodeoxycholsäure.